Surgery Partners, Inc.
HealthcareNASDAQ:SGRY · NASDAQ Global Select
+$0.37 today
Vol 1.22M · Avg 1.36M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$3.3B of revenue converted into -$76.1M of net income for the selected period. Gross margin is 21.6% and net margin is -2.3%, showing how much revenue survives after costs and taxes. EPS is $-0.59, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3B +6.2% | $3.1B +13.5% | $2.7B +8.0% | $2.5B +14.1% | $2.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.5B +7.4% | $2.4B +13.0% | $2.1B +6.7% | $2.0B +13.3% | $1.7B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $765.0M +2.6% | $745.6M +15.2% | $647.5M +12.6% | $574.9M +17.0% | $491.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 23.1% -0.8pp | 23.9% +0.3pp | 23.6% +1.0pp | 22.6% +0.6pp | 22.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $522.7M +276.9% | $138.7M +14.7% | $120.9M +18.3% | $102.2M -1.7% | $104.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $375.5M -5.4% | $396.8M +24.2% | $319.5M +39.1% | $229.7M +21.4% | $189.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $176.0M +15.3% | $152.6M +29.2% | $118.1M +2.9% | $114.8M +16.2% | $98.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | $565.5M +12.8% | $501.4M +12.4% | $446.1M -3.0% | $460.0M +14.7% | $401.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 17.1% +1.0pp | 16.1% -0.2pp | 16.3% -1.9pp | 18.1% +0.1pp | 18.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $389.5M +11.7% | $348.8M +6.3% | $328.0M -5.0% | $345.2M +14.2% | $302.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 11.8% +0.6pp | 11.2% -0.8pp | 12.0% -1.6pp | 13.6% +0.0pp | 13.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $272.6M +35.2% | $201.7M +4.5% | $193.0M -17.8% | $234.9M +6.3% | $221.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$272.6M -35.2% | -$201.7M -4.5% | -$193.0M +17.8% | -$234.9M -6.3% | -$221.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $116.9M -20.5% | $147.1M +9.0% | $135.0M +22.4% | $110.3M +35.8% | $81.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 3.5% -1.2pp | 4.7% -0.2pp | 4.9% +0.6pp | 4.3% +0.7pp | 3.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $18.0M -86.6% | $134.6M +44966.7% | -$300.0K -101.3% | $23.3M +121.9% | $10.5M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$77.9M +53.7% | -$168.1M -1312.6% | -$11.9M +78.2% | -$54.6M +23.0% | -$70.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | -2.4% +3.0pp | -5.4% -5.0pp | -0.4% +1.7pp | -2.2% +1.0pp | -3.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +54.1% | -$1 -1304.4% | -$0 +83.9% | -$1 +47.3% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +54.1% | -$1 -1304.4% | -$0 +83.9% | -$1 +47.3% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $127.2M +0.9% | $126.1M +0.4% | $125.6M +36.6% | $92.0M +27.0% | $72.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $127.2M +0.9% | $126.1M +0.4% | $125.6M +36.6% | $92.0M +27.0% | $72.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.63B
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
LivaNova PLC
NASDAQ:LIVN
$4.36B
Brookdale Senior Living Inc.
NYSE:BKD
$3.21B
Heartflow, Inc. Common Stock
NASDAQ:HTFL
$2.87B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Ardent Health Partners, LLC
NYSE:ARDT
$1.34B
Alphatec Holdings, Inc.
NASDAQ:ATEC
$1.27B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SGRY generate?
Surgery Partners, Inc. (SGRY) reported $3.31B of revenue in fiscal 2025.
Is SGRY profitable?
Surgery Partners, Inc. (SGRY) reported -$77,900,000.00 of net income, with a net margin of -2.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.